BibTex RIS Kaynak Göster

Manisa Şehzadeler Eğitim Araştırma Toplum Sağlığı Bölgesinde Seçilen Kentsel ve Yarı-Kentsel Bölgelerde 10 Yıllık Diyabet Riski ve İlişkili Faktörler

Yıl 2019, Cilt: 5 Sayı: 1, 47 - 54, 01.01.2019

Öz

Amaç: Bu çalışmanın amacı Manisa Şehzadeler Eğitim Araştırma Toplum Sağlığı Merkezi bölgesinde seçilen kentsel ve yarı kentsel bölgelerde 10 yıllık diyabet riski ve ilişkili faktörleri incelemektir.Gereç ve Yöntemler: Kesitsel tipteki çalışma Mart 2017’da Manisa Şehzadeler bölgesinde bir yarı kentsel ve bir kentsel bölgede 20-65 yaş üzerinde yürütülmüştür. 4505 kişilik evrenden küme örnekleme yöntemi ile seçilmiş 396 kişiye Tip 2 Diyabet riskini ölçen FINDRISC Finlandiya Diyabet Risk Skorlaması ölçeği ile kişisel özelliklerin sorgulandığı bir anket formu uygulanmıştır.Bulgular: Çalışmaya katılanların yaş ortalaması 46,4±12,1 ve katılımcıların %67,0’ı kadındır. FINDRISC skorlamasına göre 10 yıllık diyabet riski açısından katılımcıların %60,6’sı düşük veya hafif riskli, %18,7’si orta riskli ve %20,7’si yüksek veya çok yüksek risklidir. Aynı zamanda çalışmaya katılanların %12,1’i kendisinin diyabet olduğunu belirtmiştir. Çoklu analiz sonucunda; diyabet riski geniş ailede yaşayanlarda 2,32 kat OR: 2,32; %95GA=1,04-5,16 , parçalanmış ailede yaşayanlarda 3,18 kat OR:3,18; %95GA=1,13-8,39 , geliri giderinden az olanlarda 3,77 kat OR:3,77; %95GA=1,12-12,71 fazladır. Ayrıca diyabet riski sürekli ilaç kullanımında 4,23 kat OR:4,23; %95GA=2,17-8,27 ve kolesterol yüksekliğinde 3,10 kat OR:3,10; %95GA=1,65-5,84 artmaktadır. Sonuç: Ülkemizde hızla artan diyabet gelişiminin ve komplikasyonlarının önlenmesi için erken tanı ve risk gruplarının tanımlanması büyük önem taşımaktadır

Kaynakça

  • 1. International Diabetes Federation. 7th Diabetes Atlas. United Kingdom: IDF Publication, 2015.
  • 2. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28:169-80.
  • 3. Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, Bastar I, Tutuncu Y, Sargın M, Dinccag N, Karsidag K, Kalaca S, Ozcan C, King H. Population-based study of diabetes and risk characteristics in Turkey: Results of the Turkish Diabetes Epidemiology Study (TURDEP). Diabetes Care 2002; 25(9):1551-6.
  • 4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
  • 5. Group DPPR; Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677-86.
  • 6. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34 Suppl 1:S11-61.
  • 7. Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J, Sheppard KE, Charlesworth K, Felton AM, Hall M, Rissanen A, Tuomilehto J, Schwarz PE, Roden M et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010; 42 Suppl 1:S3-36.
  • 8. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: A consensus on type 2 diabetes prevention. Diabet Med 2007; 24:451-63.
  • 9. Lindstrom J, Tuomilehto J. The diabetes risk score: A practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26:725-31.
  • 10. Chen L, Magliano DJ, Balkau B, Colagiuri S, Zimmet PZ, Tonkin AM, Mitchell P, Phillips PJ, Shaw JE. AUSDRISK: An australian type 2 diabetes risk assessment tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust 2010; 192:197-202.
  • 11. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, Fumeron F, Froguel P, Vaxillaire M, Cauchi S, Ducimetière P, Eschwège E. Predicting diabetes: Clinical, biological, and genetic approaches: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2008; 31:2056-61.
  • 12. Rosella LC, Manuel DG, Burchill C, Stukel TA. A population-based risk algorithm for the development of diabetes: Development and validation of the Diabetes Population Risk Tool (DPoRT). J Epidemiol Community Health 2011; 65:613-20.
  • 13. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QD Score. BMJ 2009; 338:b880.
  • 14. Abbasi A, Peelen LM, Corpeleijn E, Van der Schouw YT, Stolk RP, Spijkerman AMW, Van der A DL, Moons KGM, Navis G, Bakker S, Beulens J. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ 2012; 345:e5900.
  • 15. Kengn A, Beulens J, Peelen L, Moons KGM, Van der Schouw YT, Schulz MB, Spijkerman AMW, Griffin SJ, Grobbe DE, Palla L, Tormo MJ, Arriola L, Barrengo NC, Barricarte A, Boeing H, Bonet C, Clavel-Chapelon F, Dartois L, Fagherazzi G, Franks PW, Huerta JM, Kaaks R, Key TJ, Khaw KT, Li K, Mühlenbruch K, Nilsson PM, Overvad K, Overvad TF, Palli D, Panico S, Quiros R, Rolandsson O, Roswall N, Sacerdote C, Sanchez MJ, Slimani N, Tagliabue G, Tjonneland A, Tumino R, Van der A DL, Forouhi NG, Sharp SJ, Langenberg C, Riboli E, Wareham NJ. Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): A validation of existing models. Lancet 2014; 2:19-29.
  • 16. Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, Katsilambros N. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab 2011; 37(2):144–51.
  • 17. Salinero-Fort MA, Burgos-Lunar C, Lahoz, C, Mostaza, JM, Abánades-Herranz JC, Laguna-Cuesta F, Estirado-de Cabo E, Garcia-Iglesias F, Gonzalez-Allegre T, FernandezPuntero B, Montesano-Sanchez L, Vincent-Lopez D, Cornejo-del Rio V, Fernandez-Garcia PJ, Sanchez-Arroyo V, Sabin-Rodriguez C, Lopez-Lopez S, Patron-Barandio P, Gomez-Campelo P. Performance of the Finnish Diabetes Risk Score and a Simplified Finnish Diabetes Risk Score in a Community-Based, Cross-Sectional Programme for Screening of Undiagnosed Type 2 Diabetes Mellitus and Dysglycaemia in Madrid, Spain: The SPREDIA-2 Study. PloSone 2016; 11(7):e0158489.
  • 18. Selçuk KT. Bigadiç’te 45-74 Yaş Bireylerde Tip 2 Diyabet Riskinin Belirlenmesi. Doktora Tezi, İzmir, 2013.
  • 19. Kılıç M, Cetinkaya F, Kılıc AI. Predicting risk of type 2 diabetes mellitus: A population-based study. Journal of Clinical and Analytical Medicine 2015; 6 Suppl 6:850-4.
  • 20. Saaristo T, Peltonen M, Lindström J, Saarikoski L, Sundvall J, Eriksson JG, Tuomilehto J. Cross-sectional evaluation of the finnish diabetes risk score: A tool to identify undetected type2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diabetes and Vascular Disease Research 2005; 2(2):67-72.
  • 21. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML. International physical activity questionnaire: 12-country reliability and validity. Medicine and Science in Sports and Exercise 2003; 35:1381-95.
  • 22. Karaca A, Turnagöl H. IPAQ anketinin geçerlilik ve güvenirlilik çalışması. Hacettepe Üniversitesi Spor Bilimleri Dergisi 2007; 18(2):68-84.
  • 23. Cos FX, Barengo NC, Costa B, Mundet-Tuduri X, Lindström J, Tuomilehto JO. Screening for people with abnormal glucose metabolism in the European DEPLAN Project. Diabetes Research and Clinical Practice 2015; 109:149-56.
  • 24. Kutlu R, Sayın S, Koçak A. Tanı almamış tip 2 diyabet için bir tarama metodu olarak Fin diyabet risk anketi (FINDRISK) uygulanabilirmi? Konuralp Tıp Dergisi 2016; 8(3):158-66.
  • 25. Zhang L, Zhang Z, Zhang Y, Chen L. Evaluation of Finnish Diabetes Risk Score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: NHANES 1999-2010. PLoSOne 2014; 9(5):e97865.
  • 26. Türkiye Endokrinoloji ve Metabolizma Derneği. Diabetes Mellitus ve Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu 2013. Ankara: BAYT Bilimsel Araştırmalar, 2014.
  • 27. Onat A, Can G, Yüksel H. TEKHARF 2017 Tıp Dünyasının Kronik Hastalıklara Yaklaşımına Öncülük. Türkiye Kardiyoloji Derneği. Erişim adresi: http://file. tkd.org.tr/PDFs/TEKHARF-2017.pdf (23.10.2017)
  • 28. Boratav K. Sınıfların ve Grupların Sosyoekonomik Nitelikleri. 2. Baskı. Ankara: İmge Kitapevi, 2004:33-60.
  • 29. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. Türkiye Diyabet Programı 2015-2020. Ankara: Kuban Matbaacılık Yayıncılık, 2014.

10-Year Diabetes Risk and Associated Factors in Selected Urban and Semi-Urban Areas in the Manisa Şehzadeler Education-Research Community Health District

Yıl 2019, Cilt: 5 Sayı: 1, 47 - 54, 01.01.2019

Öz

Objective: The aim of this study was to determine the 10-year risk of diabetes in adults in selected semi-urban and urban populations at the Manisa Sehzadeler Education-Research Community Health Centre district. Material and Methods: This study was a cross-sectional study in subjects aged 20-65 years in urban and semi-urban Family Health Center areas. A questionnaire was applied for the FINDRISC Finnish Diabetes Risk Scale scale, which measures Type 2 diabetes risk, to 396 individuals selected by the cluster sampling method from 4505 subjects.Results: The mean age of the participants was 46.4±12.1 years and 67.0% of the participants were female. According to the FINDRISC score, 60.6% of the participants were at very low or low risk, 18.7% at moderate risk and 20.7% at high or very high risk regarding the 10-year risk of diabetes. At the same time, 12.1% of those who participated in the study stated that they had diabetes. The risk of diabetes is 2.32 times more 95% CI=1.04-5.16 in those living in a large family, 3.18 times more 95% CI=1.13-8.39 in those living in a shattered family, and 3.77 times more 95% CI=1.12-12.71 in those with lower income than their expenses. In addition, the risk of diabetes increased 4.23 times 95% CI=2.17-8.27 with continuous medication use and 3.10 times 95% CI=1.65 -5.84 in those with high cholesterol levels. Conclusion: Identification of risk groups and early diagnosis is crucial for the prevention of diabetes development and complications, both of which are increasing rapidly in our country

Kaynakça

  • 1. International Diabetes Federation. 7th Diabetes Atlas. United Kingdom: IDF Publication, 2015.
  • 2. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28:169-80.
  • 3. Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, Bastar I, Tutuncu Y, Sargın M, Dinccag N, Karsidag K, Kalaca S, Ozcan C, King H. Population-based study of diabetes and risk characteristics in Turkey: Results of the Turkish Diabetes Epidemiology Study (TURDEP). Diabetes Care 2002; 25(9):1551-6.
  • 4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
  • 5. Group DPPR; Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677-86.
  • 6. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34 Suppl 1:S11-61.
  • 7. Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J, Sheppard KE, Charlesworth K, Felton AM, Hall M, Rissanen A, Tuomilehto J, Schwarz PE, Roden M et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010; 42 Suppl 1:S3-36.
  • 8. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: A consensus on type 2 diabetes prevention. Diabet Med 2007; 24:451-63.
  • 9. Lindstrom J, Tuomilehto J. The diabetes risk score: A practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26:725-31.
  • 10. Chen L, Magliano DJ, Balkau B, Colagiuri S, Zimmet PZ, Tonkin AM, Mitchell P, Phillips PJ, Shaw JE. AUSDRISK: An australian type 2 diabetes risk assessment tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust 2010; 192:197-202.
  • 11. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, Fumeron F, Froguel P, Vaxillaire M, Cauchi S, Ducimetière P, Eschwège E. Predicting diabetes: Clinical, biological, and genetic approaches: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2008; 31:2056-61.
  • 12. Rosella LC, Manuel DG, Burchill C, Stukel TA. A population-based risk algorithm for the development of diabetes: Development and validation of the Diabetes Population Risk Tool (DPoRT). J Epidemiol Community Health 2011; 65:613-20.
  • 13. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QD Score. BMJ 2009; 338:b880.
  • 14. Abbasi A, Peelen LM, Corpeleijn E, Van der Schouw YT, Stolk RP, Spijkerman AMW, Van der A DL, Moons KGM, Navis G, Bakker S, Beulens J. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ 2012; 345:e5900.
  • 15. Kengn A, Beulens J, Peelen L, Moons KGM, Van der Schouw YT, Schulz MB, Spijkerman AMW, Griffin SJ, Grobbe DE, Palla L, Tormo MJ, Arriola L, Barrengo NC, Barricarte A, Boeing H, Bonet C, Clavel-Chapelon F, Dartois L, Fagherazzi G, Franks PW, Huerta JM, Kaaks R, Key TJ, Khaw KT, Li K, Mühlenbruch K, Nilsson PM, Overvad K, Overvad TF, Palli D, Panico S, Quiros R, Rolandsson O, Roswall N, Sacerdote C, Sanchez MJ, Slimani N, Tagliabue G, Tjonneland A, Tumino R, Van der A DL, Forouhi NG, Sharp SJ, Langenberg C, Riboli E, Wareham NJ. Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): A validation of existing models. Lancet 2014; 2:19-29.
  • 16. Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, Katsilambros N. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab 2011; 37(2):144–51.
  • 17. Salinero-Fort MA, Burgos-Lunar C, Lahoz, C, Mostaza, JM, Abánades-Herranz JC, Laguna-Cuesta F, Estirado-de Cabo E, Garcia-Iglesias F, Gonzalez-Allegre T, FernandezPuntero B, Montesano-Sanchez L, Vincent-Lopez D, Cornejo-del Rio V, Fernandez-Garcia PJ, Sanchez-Arroyo V, Sabin-Rodriguez C, Lopez-Lopez S, Patron-Barandio P, Gomez-Campelo P. Performance of the Finnish Diabetes Risk Score and a Simplified Finnish Diabetes Risk Score in a Community-Based, Cross-Sectional Programme for Screening of Undiagnosed Type 2 Diabetes Mellitus and Dysglycaemia in Madrid, Spain: The SPREDIA-2 Study. PloSone 2016; 11(7):e0158489.
  • 18. Selçuk KT. Bigadiç’te 45-74 Yaş Bireylerde Tip 2 Diyabet Riskinin Belirlenmesi. Doktora Tezi, İzmir, 2013.
  • 19. Kılıç M, Cetinkaya F, Kılıc AI. Predicting risk of type 2 diabetes mellitus: A population-based study. Journal of Clinical and Analytical Medicine 2015; 6 Suppl 6:850-4.
  • 20. Saaristo T, Peltonen M, Lindström J, Saarikoski L, Sundvall J, Eriksson JG, Tuomilehto J. Cross-sectional evaluation of the finnish diabetes risk score: A tool to identify undetected type2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diabetes and Vascular Disease Research 2005; 2(2):67-72.
  • 21. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML. International physical activity questionnaire: 12-country reliability and validity. Medicine and Science in Sports and Exercise 2003; 35:1381-95.
  • 22. Karaca A, Turnagöl H. IPAQ anketinin geçerlilik ve güvenirlilik çalışması. Hacettepe Üniversitesi Spor Bilimleri Dergisi 2007; 18(2):68-84.
  • 23. Cos FX, Barengo NC, Costa B, Mundet-Tuduri X, Lindström J, Tuomilehto JO. Screening for people with abnormal glucose metabolism in the European DEPLAN Project. Diabetes Research and Clinical Practice 2015; 109:149-56.
  • 24. Kutlu R, Sayın S, Koçak A. Tanı almamış tip 2 diyabet için bir tarama metodu olarak Fin diyabet risk anketi (FINDRISK) uygulanabilirmi? Konuralp Tıp Dergisi 2016; 8(3):158-66.
  • 25. Zhang L, Zhang Z, Zhang Y, Chen L. Evaluation of Finnish Diabetes Risk Score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: NHANES 1999-2010. PLoSOne 2014; 9(5):e97865.
  • 26. Türkiye Endokrinoloji ve Metabolizma Derneği. Diabetes Mellitus ve Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu 2013. Ankara: BAYT Bilimsel Araştırmalar, 2014.
  • 27. Onat A, Can G, Yüksel H. TEKHARF 2017 Tıp Dünyasının Kronik Hastalıklara Yaklaşımına Öncülük. Türkiye Kardiyoloji Derneği. Erişim adresi: http://file. tkd.org.tr/PDFs/TEKHARF-2017.pdf (23.10.2017)
  • 28. Boratav K. Sınıfların ve Grupların Sosyoekonomik Nitelikleri. 2. Baskı. Ankara: İmge Kitapevi, 2004:33-60.
  • 29. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. Türkiye Diyabet Programı 2015-2020. Ankara: Kuban Matbaacılık Yayıncılık, 2014.
Toplam 29 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Araştırma Makalesi
Yazarlar

Tayfun Alperen Esgin Bu kişi benim

Saliha Ünal Bu kişi benim

Pınar Erbay Dündar Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 5 Sayı: 1

Kaynak Göster

Vancouver Esgin TA, Ünal S, Erbay Dündar P. Manisa Şehzadeler Eğitim Araştırma Toplum Sağlığı Bölgesinde Seçilen Kentsel ve Yarı-Kentsel Bölgelerde 10 Yıllık Diyabet Riski ve İlişkili Faktörler. Akd Tıp D. 2019;5(1):47-54.